Wei Huang1, Rudolf K F Oliveira2, Han Lei3, David M Systrom4, Aaron B Waxman5. 1. Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Pulmonary and Critical Care Medicine, Center for Pulmonary Heart Disease, Brigham and Women's Hospital, Boston, Massachusetts. 2. Pulmonary and Critical Care Medicine, Center for Pulmonary Heart Disease, Brigham and Women's Hospital, Boston, Massachusetts; Division of Respiratory Disease, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil. 3. Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 4. Pulmonary and Critical Care Medicine, Center for Pulmonary Heart Disease, Brigham and Women's Hospital, Boston, Massachusetts. 5. Pulmonary and Critical Care Medicine, Center for Pulmonary Heart Disease, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: abwaxman@bwh.harvard.edu.
Abstract
BACKGROUND: In heart failure with preserved ejection fraction (HFpEF), the prognostic value of pulmonary vascular dysfunction (PV-dysfunction), identified by elevated pulmonary vascular resistance (PVR) at peak exercise, is not completely understood. We evaluated the long-term prognostic implications of PV-dysfunction in HFpEF during exercise in consecutive patients undergoing invasive cardiopulmonary exercise testing for unexplained dyspnea. METHODS: Patients with HFpEF were classified into 2 main groups: resting HFpEF (n = 104, 62% female, age 61 years) with a pulmonary arterial wedge pressure (PAWP) >15 mmHg at rest; and exercise HFpEF (eHFpEF; n = 81) with a PAWP <15 mmHg at rest, but >20 mmHg during exercise. The eHFpEF group was further subdivided into eHFpEF + PV-dysfunction (peak PVR ≥80 dynes/s/cm-5; n = 55, 60% female, age 64) group and eHFpEF - PV-dysfunction (peak PVR <80 dynes/s/cm-5; n = 26, 42% female, age 54 years) group. Outcomes were analyzed for the first 9 years of follow-up and included any cause mortality and heart failure (HF)-related hospitalizations. The mean follow-up time was 6.7 ± 2.6 years (0.5-9.0). RESULTS: Mortality rate did not differ among the groups. However, survival free of HF-related hospitalization was lower for the eHFpEF + PV-dysfunction group compared with eHFpEF - PV-dysfunction (P = .01). These findings were similar between eHFpEF + PV-dysfunction and the resting HFpEF group (P = .774). By Cox analysis, peak PVR ≥80 dynes/s/cm-5 was a predictor of HF-related hospitalization for eHFpEF (hazard ratio 5.73, 95% confidence interval 1.05-31.22, P = .01). In conclusion, the present study provides insight into the impact of PV-dysfunction on outcomes of patients with exercise-induced HFpEF. An elevated peak PVR is associated with a high risk of HF-related hospitalization.
BACKGROUND: In heart failure with preserved ejection fraction (HFpEF), the prognostic value of pulmonary vascular dysfunction (PV-dysfunction), identified by elevated pulmonary vascular resistance (PVR) at peak exercise, is not completely understood. We evaluated the long-term prognostic implications of PV-dysfunction in HFpEF during exercise in consecutive patients undergoing invasive cardiopulmonary exercise testing for unexplained dyspnea. METHODS:Patients with HFpEF were classified into 2 main groups: resting HFpEF (n = 104, 62% female, age 61 years) with a pulmonary arterial wedge pressure (PAWP) >15 mmHg at rest; and exercise HFpEF (eHFpEF; n = 81) with a PAWP <15 mmHg at rest, but >20 mmHg during exercise. The eHFpEF group was further subdivided into eHFpEF + PV-dysfunction (peak PVR ≥80 dynes/s/cm-5; n = 55, 60% female, age 64) group and eHFpEF - PV-dysfunction (peak PVR <80 dynes/s/cm-5; n = 26, 42% female, age 54 years) group. Outcomes were analyzed for the first 9 years of follow-up and included any cause mortality and heart failure (HF)-related hospitalizations. The mean follow-up time was 6.7 ± 2.6 years (0.5-9.0). RESULTS: Mortality rate did not differ among the groups. However, survival free of HF-related hospitalization was lower for the eHFpEF + PV-dysfunction group compared with eHFpEF - PV-dysfunction (P = .01). These findings were similar between eHFpEF + PV-dysfunction and the resting HFpEF group (P = .774). By Cox analysis, peak PVR ≥80 dynes/s/cm-5 was a predictor of HF-related hospitalization for eHFpEF (hazard ratio 5.73, 95% confidence interval 1.05-31.22, P = .01). In conclusion, the present study provides insight into the impact of PV-dysfunction on outcomes of patients with exercise-induced HFpEF. An elevated peak PVR is associated with a high risk of HF-related hospitalization.
Authors: Yogesh N V Reddy; Masaru Obokata; Katlyn E Koepp; Alexander C Egbe; Brandon Wiley; Barry A Borlaug Journal: Circ Res Date: 2019-01-18 Impact factor: 17.367
Authors: Masaru Obokata; Garvan C Kane; Yogesh N V Reddy; Vojtech Melenovsky; Thomas P Olson; Petr Jarolim; Barry A Borlaug Journal: Eur Heart J Date: 2019-12-01 Impact factor: 29.983
Authors: Barry A Borlaug; John Blair; Martin W Bergmann; Heiko Bugger; Dan Burkhoff; Leonhard Bruch; David S Celermajer; Brian Claggett; John G F Cleland; Donald E Cutlip; Ira Dauber; Jean-Christophe Eicher; Qi Gao; Thomas M Gorter; Finn Gustafsson; Chris Hayward; Jan van der Heyden; Gerd Hasenfuß; Scott L Hummel; David M Kaye; Jan Komtebedde; Joseph M Massaro; Jeremy A Mazurek; Scott McKenzie; Shamir R Mehta; Mark C Petrie; Marco C Post; Ajith Nair; Andreas Rieth; Frank E Silvestry; Scott D Solomon; Jean-Noël Trochu; Dirk J Van Veldhuisen; Ralf Westenfeld; Martin B Leon; Sanjiv J Shah Journal: Circulation Date: 2022-03-31 Impact factor: 39.918
Authors: Jan Verwerft; Frederik H Verbrugge; Guido Claessen; Lieven Herbots; Paul Dendale; Andreas B Gevaert Journal: Front Cardiovasc Med Date: 2022-02-09
Authors: Colm McCabe; Rudolf K F Oliveira; Farbod Rahaghi; Mariana Faria-Urbina; Luke Howard; Richard G Axell; Andrew N Priest; Aaron B Waxman; David M Systrom Journal: Eur J Appl Physiol Date: 2018-04-30 Impact factor: 3.078
Authors: Katarina Zeder; Chiara Banfi; Gregor Steinrisser-Allex; Bradley A Maron; Marc Humbert; Gregory D Lewis; Andrea Berghold; Horst Olschewski; Gabor Kovacs Journal: Eur Respir J Date: 2022-10-13 Impact factor: 33.795